<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04419506</url>
  </required_header>
  <id_info>
    <org_study_id>1305-0013</org_study_id>
    <secondary_id>2019-004167-45</secondary_id>
    <nct_id>NCT04419506</nct_id>
  </id_info>
  <brief_title>A Study to Test How Taking BI 1015550 for 12 Weeks Affects Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled Parallel Group Study in IPF Patients Over 12 Weeks Evaluating Efficacy, Safety and Tolerability of BI 1015550 Taken Orally</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are at least 40&#xD;
      years old. People taking standard medicines for IPF, including antifibrotic medicines, can&#xD;
      continue taking them throughout the study.&#xD;
&#xD;
      The purpose of the study is to find out whether a medicine called BI 1015550 can slow down&#xD;
      the worsening of lung function. Participants are in the study for about 4 months. During this&#xD;
      time, they visit the study site about 7 times. At the beginning, they visit the study site&#xD;
      every 2 weeks.&#xD;
&#xD;
      After 1 month of treatment, they visit the study site every 4 weeks.&#xD;
&#xD;
      The participants are put into 2 groups by chance. 1 group gets BI 1015550. The other group&#xD;
      gets placebo. Placebo tablets look like BI 1015550 tablets but contain no medicine. The&#xD;
      participants take BI 1015550 or placebo tablets twice a day.&#xD;
&#xD;
      The participants have lung function tests at study visits. The results of the lung function&#xD;
      tests are compared between the BI 1015550 group and the placebo group. The doctors also&#xD;
      regularly check the general health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 28, 2020</start_date>
  <completion_date type="Actual">October 15, 2021</completion_date>
  <primary_completion_date type="Actual">October 6, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>change from baseline in Forced Vital Capacity (FVC)</measure>
    <time_frame>up to 12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>percentage of patients with Treatment Emergent Adverse Events (TEAE)</measure>
    <time_frame>up to 13 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Idiopathic Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>BI 1015550</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 1015550</intervention_name>
    <description>film-coated tablet</description>
    <arm_group_label>BI 1015550</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>film-coated tablet</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients aged ≥40 years when signing the informed consent.&#xD;
&#xD;
          2. Diagnosis:&#xD;
&#xD;
               1. IPF based on 2018 ATS/ERS/JRS/ALAT Guideline as confirmed by the investigator&#xD;
                  based on chest High Resolution Computed Tomography Scan (HRCT) scan taken within&#xD;
                  12 months of Visit 1 and if available surgical lung biopsy.&#xD;
&#xD;
                  and&#xD;
&#xD;
               2. Usual interstitial pneumonia (UIP) or probable UIP HRCT pattern consistent with&#xD;
                  the clinical diagnosis of IPF, as confirmed by central review prior to Visit 2*&#xD;
&#xD;
                    -  if indeterminate HRCT finding IPF may be confirmed locally by (historical)&#xD;
                       biopsy&#xD;
&#xD;
          3. Stable for at least 8 weeks prior to Visit 1. Patients have to be either :&#xD;
&#xD;
               -  not on therapy with nintedanib or pirfenidone for at least 8 weeks prior to Visit&#xD;
                  1 (combination of nintedanib plus pirfenidone not allowed), or&#xD;
&#xD;
               -  on stable* therapy with nintedanib or pirfenidone for at least 8 weeks prior to&#xD;
                  Visit 1 and planning to stay stable on this background therapy after&#xD;
                  randomisation.&#xD;
&#xD;
             [*stable therapy is defined as the individually and general tolerated regimen of&#xD;
             either pirfenidone or nintedanib]&#xD;
&#xD;
          4. Forced Vital Capacity (FVC) ≥45% of predicted normal at Visit 1&#xD;
&#xD;
          5. Diffusion capacity of the lung for carbon monoxide (DLCO) (corrected for haemoglobin&#xD;
             [Hb] [Visit 1]) ≥ 25% to &lt; 80% of predicted normal at Visit 1.&#xD;
&#xD;
          6. Signed and dated written informed consent in accordance with ICH-GCP and local&#xD;
             legislation prior to admission to the trial.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Relevant airways obstruction (pre-bronchodilator Forced Expiratory Volume in one&#xD;
             second (FEV1)/Forced Vital Capacity (FVC) &lt; 0.7) at Visit 1.&#xD;
&#xD;
          2. In the opinion of the Investigator, other clinically significant pulmonary&#xD;
             abnormalities.&#xD;
&#xD;
          3. Acute IPF exacerbation within 4 months prior to screening and/or during the screening&#xD;
             period (investigator-determined).&#xD;
&#xD;
          4. Lower respiratory tract infection requiring antibiotics within 4 weeks prior to Visit&#xD;
             1 and/or during the screening period.&#xD;
&#xD;
          5. Major surgery (major according to the investigator's assessment) performed within 3&#xD;
             months prior to Visit 1 or planned during the course of the trial. (Being on a&#xD;
             transplant list is allowed).&#xD;
&#xD;
          6. Any documented active or suspected malignancy or history of malignancy within 5 years&#xD;
             prior to Visit 1, except appropriately treated basal cell carcinoma of the skin,&#xD;
             &quot;under surveillance&quot; prostate cancer or in situ carcinoma of uterine cervix.&#xD;
&#xD;
          7. Evidence of active infection (chronic or acute) based on clinical exam or laboratory&#xD;
             findings at Visit 1 or at Visit 2.&#xD;
&#xD;
          8. Any suicidal behaviour in the past 2 years (i.e. actual attempt, interrupted attempt,&#xD;
             aborted attempt, or preparatory acts or behavior).&#xD;
&#xD;
          9. The patient has a confirmed infection with SARS-CoV-2 within the 4 weeks prior to&#xD;
             Visit 1 and/or during the screening period.&#xD;
&#xD;
        Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Florida</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Metabólicas (CINME)</name>
      <address>
        <city>C.a.b.a</city>
        <zip>C1027AAP</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alfred Hospital</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LKH-Univ. Hospital Graz</name>
      <address>
        <city>Graz</city>
        <zip>8036</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Syed Anees Medicine Professional Corporation</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 1T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigación del Maule</name>
      <address>
        <city>Talca</city>
        <zip>3465586</zip>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <zip>130041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomayer Hospital</name>
      <address>
        <city>Praha 4 - Krc</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HYKS Keuhkosairauksien tutkimusyksikkö</name>
      <address>
        <city>Helsinki</city>
        <zip>00290</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fachkrankenhaus Coswig GmbH</name>
      <address>
        <city>Coswig</city>
        <zip>01640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Crete</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Semmelweis University</name>
      <address>
        <city>Budapest</city>
        <zip>1085</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tosei General Hospital</name>
      <address>
        <city>Aichi, Seto</city>
        <zip>489-8642</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Bucheon St.Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <zip>14647</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zuyderland Medisch Centrum</name>
      <address>
        <city>Heerlen</city>
        <zip>6419 PC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Center, Gdansk</name>
      <address>
        <city>Gdansk</city>
        <zip>80-214</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moscow 1st State Med.Univ.n.a.I.M.Sechenov</name>
      <address>
        <city>Moscow</city>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instit.Phthisiology&amp;Pulmon.na Yanovskiy,Non-Specif.Lung,Kyiv</name>
      <address>
        <city>Kyiv</city>
        <zip>03680</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Brompton Hospital</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Canada</country>
    <country>Chile</country>
    <country>China</country>
    <country>Czechia</country>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 5, 2020</study_first_posted>
  <last_update_submitted>October 29, 2021</last_update_submitted>
  <last_update_submitted_qc>October 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Idiopathic Pulmonary Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

